癌相关成纤维细胞在非小细胞肺癌进展中的作用

doi:10.11904/j.issn.1002-3070.2023.04.014

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (4): 383-388.doi: 10.11904/j.issn.1002-3070.2023.04.014

• 综述 • 上一篇

癌相关成纤维细胞在非小细胞肺癌进展中的作用

曹莹月¹, 庞露薏², 张键³ 综述, 金时⁴ 审校

1.川北医学院基础医学与法医学研究所(南充 637100);
2.南方科技大学生物医学系;
3.中国科学院深圳先进技术研究院能量代谢与生殖研究中心;
4.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院肿瘤内科

收稿日期:2023-06-11 修回日期:2023-09-20 出版日期:2023-08-28 发布日期:2023-12-12
通讯作者: 金时,E-mail:catherine-jinshi@163.com
作者简介:曹莹月,女,(1991-),博士研究生,从事肿瘤转移微环境及肿瘤免疫的研究。
基金资助:
深圳市科技计划项目(编号:RCJC20200714114436049);深圳市代谢健康重点实验室(编号:ZDSYS20210427152400001);中国医学科学院肿瘤医院深圳医院/深圳市肿瘤医院科研项目(编号:SZ2020ZD006)

The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer

CAO Yingyue¹, PANG Luyi², ZHANG Jian³, JIN Shi⁴

1. Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong 637100, China;
2. Department of Biomedicine, Southern University of Science and Technology;
3. Center for Energy Metabolism and Reproduction, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences;
4. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Perking Union Medical College

Received:2023-06-11 Revised:2023-09-20 Online:2023-08-28 Published:2023-12-12

摘要/Abstract

摘要： 癌相关成纤维细胞(Cancer-associated fibroblasts,CAFs)是基质和相关肿瘤微环境中的主要成分,在非小细胞肺癌(Non-small cell lung cancer,NSCLC)的发生发展过程中发挥重要的作用。研究表明,CAFs通过分泌多种类型的细胞因子、趋化因子、生长因子和细胞外基质蛋白,参与调控癌细胞的增殖、侵袭、转移和对化疗药物的耐药性。本文将从CAFs的来源、活化机制及其在NSCLC发生发展过程中的作用进行综述,以深入了解NSCLC进展机制并为其治疗提供新思路。

关键词: 癌相关成纤维细胞, 肿瘤微环境, 非小细胞肺癌

Abstract: Cancer-associated fibroblasts(CAFs)are the main components of the matrix and associated tumor microenvironment, playing an important role in the occurrence and development of non-small cell lung cancer(NSCLC). Many studies have demonstrated that CAFs are involved in regulating the proliferation, invasion, metastasis, and resistance to chemotherapy drugs of cancer cells by secreting various types of cytokines and chemokines, growth factors, and extracellular matrix proteins. This article will review the source, activation mechanisms, and role of CAFs in the occurrence and development of NSCLC, so as to gain a deeply understanding the progression mechanism of NSCLC and provide new ideas for its treatment.

Key words: Cancer-associated fibroblasts, Tumor microenvironment, Non-small cell lung cancer

中图分类号:

R734.2

曹莹月, 庞露薏, 张键, 金时. 癌相关成纤维细胞在非小细胞肺癌进展中的作用[J]. 实用肿瘤学杂志, 2023, 37(4): 383-388.

CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer[J]. Journal of Practical Oncology, 2023, 37(4): 383-388.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.04.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I4/383

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Hirsch FR,Scagliotti GV,Mulshine JL,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311.
3 Erez N,Truitt M,Olson P,et al.Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner[J].Cancer Cell,2010,17(2):135-147.
4 Wu F,Yang J,Liu J,et al.Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer[J].Signal Transduct Target Ther,2021,6(1):218.
5 Shintani Y,Fujiwara A,Kimura T,et al.IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling[J].J Thorac Oncol,2016,11(9):1482-1492.
6 Shintani Y,Kimura T,Funaki S,et al.Therapeutic targeting of cancer-associated fibroblasts in the non-small cell lung cancer tumor microenvironment[J].Cancers(Basel),2023,15(2).335.
7 Orimo A,Weinberg RA.Heterogeneity of stromal fibroblasts in tumors[J].Cancer Biol Ther,2007,6(4):618-619.
8 Sugimoto H,Mundel TM,Kieran MW,et al.Identification of fibroblast heterogeneity in the tumor microenvironment[J].Cancer Biol Ther,2006,5(12):1640-1646.
9 Pietras K,Sjoblom T,Rubin K,et al.PDGF receptors as cancer drug targets[J].Cancer Cell,2003,3(5):439-443.
10 Kalluri R.The biology and function of fibroblasts in cancer[J].Nat Rev Cancer,2016,16(9):582-598.
11 Aoyagi Y,Yokose T,Minami Y,et al.Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma[J].Cancer Res,2001,61(21):7950-7954.
12 Petersen OW,Nielsen HL,Gudjonsson T,et al.Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma[J].Am J Pathol,2003,162(2):391-402.
13 Borriello L,Nakata R,Sheard MA,et al.Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells[J].Cancer Res,2017,77(18):5142-5157.
14 Chen H,Zhao L,Meng Y,et al.Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression[J].Cancer Lett,2022,536:215611.
15 Shi L,Zhu W,Huang Y,et al.Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer[J].Clin Transl Med,2022,12(7):e989.
16 Gentles AJ,Hui AB,Feng W,et al.A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk[J].Genome Biol,2020,21(1):107.
17 Tyan SW,Kuo WH,Huang CK,et al.Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis[J].PLoS One,2011,6(1):e15313.
18 Shien K,Papadimitrakopoulou VA,Ruder D,et al.JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer[J].Mol Cancer Ther,2017,16(10):2234-2245.
19 Zhuang H,Jiang H,Zhu L,et al.Cancer-associated fibroblasts in non-small cell lung cancer:recent advances and future perspectives[J].Cancer Lett,2021,5(14):38-47.
20 Kim SH,Choe C,Shin YS,et al.Human lung cancer-associated fibroblasts enhance motility of non-small cell lung cancer cells in co-culture[J].Anticancer Res,2013,33(5):2001-2009.
21 Saito RA,Micke P,Paulsson J,et al.Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer[J].Cancer Res,2010,70(7):2644-2654.
22 Xu LN,Xu BN,Cai J,et al.Tumor-associated fibroblast-conditioned medium promotes tumor cell proliferation and angiogenesis[J].Genet Mol Res,2013,12(4):5863-5871.
23 Fromigue O,Louis K,Dayem M,et al.Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation,angiogenesis,cell growth and survival[J].Oncogene,2003,22(52):8487-8497.
24 Chi JY,Hsiao YW,Liu HL,et al.Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4[J].Cell Death Discov,2021,7(1):94.
25 Tran E,Chinnasamy D,Yu Z,et al.Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia[J].J Exp Med,2013,210(6):1125-1135.
26 Galindo M,Santiago B,Rivero M,et al.Chemokine expression by systemic sclerosis fibroblasts:abnormal regulation of monocyte chemoattractant protein 1 expression[J].Arthritis Rheum,2001,44(6):1382-1386.
27 Kinoshita T,Ishii G,Hiraoka N,et al.Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma[J].Cancer Sci,2013,104(4):409-415.
28 Inoue C,Miki Y,Saito R,et al.PD-L1 Induction by cancer-qssociated fibroblast-derived factors in lung qdenocarcinoma cells[J].Cancers(Basel),2019,11(9):1257.
29 Teramoto K,Igarashi T,Kataoka Y,et al.Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer[J].Lung Cancer,2019,137:56-63.
30 Lakins MA,Ghorani E,Munir H,et al.Cancer-associated fibroblasts induce antigen-specific deletion of CD8(+)T Cells to protect tumour cells[J].Nat Commun,2018,9(1):948.
31 Liu T,Zhou L,Li D,et al.Cancer-associated fibroblasts build and secure the tumor microenvironment[J].Front Cell Dev Biol,2019,7:60.
32 Calco F,Ege N,Grande-Garcia A,et al.Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts[J].Nat Cell Biol,2013,15(6):637-646.
33 Santos AM,Jung J,Aziz N,et al.Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice[J].J Clin Invest,2009,119(12):3613-3625.
34 De P,Aske J,Sulaiman R,et al.Bete noire of chemotherapy and targeted therapy:CAF-mediated resistance[J].Cancers(Basel),2022,14(6):1519.
35 Scott AM,Wiseman G,Welt S,et al.A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer[J].Clin Cancer Res,2003,9(5):1639-1647.
36 Eager RM,Cunningham CC,Senzer N,et al.Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer[J].Clin Oncol(R Coll Radiol),2009,21(6):464-472.
37 Sum E,Rapp M,Durr H,et al.The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation[J].J Immunother Cancer,2022,10(3):e003264.
38 Sum E,Rapp M,Frobel P,et al.Fibroblast activation protein alpha-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity[J].Clin Cancer Res,2021,27(14):4036-4053.
39 Duperret EK,Trautz A,Ammons D,et al.Alteration of the tumor stroma using a consensus DNA vaccine targeting fibroblast activation protein(FAP)synergizes with antitumor vaccine therapy in mice[J].Clin Cancer Res,2018,24(5):1190-1201.
40 Xie J,Yuan S,Peng L,et al.Antitumor immunity targeting fibroblast activation protein-alpha in a mouse lewis lung carcinoma model[J].Oncol Lett,2020,20(1):868-876.
41 Kakarla S,Chow KK,Mata M,et al.Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma[J].Mol Ther,2013,21(8):1611-1620.
42 Bayliss TJ,Smith JT,Schuster M,et al.A humanized anti-IL-6 antibody(ALD518)in non-small cell lung cancer[J].Expert Opin Biol Ther,2011,11(12):1663-1668.
43 Dijkgraaf EM,Santegoets SJ,Reyners AK,et al.A phase I trial combining carboplatin/doxorubicin with tocilizumab,an anti-IL-6R monoclonal antibody,and interferon-alpha2b in patients with recurrent epithelial ovarian cancer[J].Ann Oncol,2015,26(10):2141-2149.
44 Hegab AE,Ozaki M,Kameyama N,et al.Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts[J].J Pathol,2019,249(2):193-205.
45 Xiang H,Ramil CP,Hai J,et al.Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma[J].Cancer Immunol Res,2020,8(4):436-450.

[1]	苗玲, 赵之寒, 王敏. 非小细胞肺癌患者肿瘤组织PA28γ、miR-7-5p的表达水平及临床意义[J]. 实用肿瘤学杂志, 2023, 37(4): 344-350.
[2]	陈琪, 何明旭, 贾科良, 苗健龙, 韩丽萍. TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 262-266.
[3]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.
[4]	刘欣欣, 马西元, 缪美琪, 王语晴, 陈晶. IL-6及其受体在乳腺癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 149-154.
[5]	徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.
[6]	张淑敏, 张弓. ILC2s在肿瘤免疫调控中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 566-569.
[7]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[8]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[9]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.
[10]	孙阜圣, 徐冶, 张永健, 娄阁. 卵巢癌类器官模型的研究进展和治疗新策略[J]. 实用肿瘤学杂志, 2022, 36(4): 346-350.
[11]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[12]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[13]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[14]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[15]	张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.

癌相关成纤维细胞在非小细胞肺癌进展中的作用

The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价